<DOC>
	<DOCNO>NCT02332902</DOCNO>
	<brief_summary>This trial evaluate use oral Everolimus determine reduction size disfigure cutaneous lesion patient Neurofibromatosis 1 6 month period . The evaluation do 3D photography measuring volume LIFEVIZ Micro system .</brief_summary>
	<brief_title>Everolimus Treatment Disfiguring Cutaneous Lesions Neurofibromatosis1 CRAD001CUS232T</brief_title>
	<detailed_description>Qualifying subject diagnosis Neurofibromatosis 1 disfigure cutaneous lesion measure photography . The subject photograph target lesion , biopsy lesion , safety blood laboratory test 3 time point ( baseline , 3 month 6 month end treatment ) . Everolimus take orally 6 month . Subjects visit clinic monthly exam adverse event evaluation . Laboratory test do visit determine necessary PI .</detailed_description>
	<mesh_term>Neurofibromatoses</mesh_term>
	<mesh_term>Neurofibroma</mesh_term>
	<mesh_term>Neurofibromatosis 1</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>1 . Patient least 18 year age time enrollment 2 . Informed consent 3 . Compliance trial requirement ( photography , lab draw , medication schedule , study visit ) 4 . Diagnosis NF 1 cutaneous neurofibromas locate region amenable photography 5 . Females child bear potential must pregnant confirmed negative pregnancy test ( blood betahCG level ) prior study enrollment must agree use appropriate contraceptive method duration trial 6 . Patient must adequate liver function show , total bilirubin &lt; /= 2.0 mg/dL , ALT AST &lt; /= 2.5 X ULN , INR &lt; /= 2 8 . Patient must adequate renal function , serum creatinine &lt; /= 1.5 X ULN 9 . Patient must adequate lipid profile , fast serum cholesterol &lt; /= 300 mg/dL OR &lt; /= 7.75 mmol/L , fast triglyceride &lt; /= X ULN 1 . Patients currently receive anticancer therapy receive anticancer therapy within 4 week start Everolimus ( include chemotherapy , radiation therapy , antibody base therapy , etc . ) 2 . Known intolerance hypersensitivity Everolimus rapamycin analog ( e.g . sirolimus , temsirolimus ) 3 . Known impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral Everolimus 4 . Uncontrolled diabetes mellitus despite adequate therapy 5 . Patients severe /or uncontrolled medical condition : unstable angina pectoris , symptomatic congestive heart failure , myocardial infarction &lt; /= prior start Everolimus , serious uncontrolled cardiac arrhythmia , clinically significant cardiac disease , symptomatic congestive heart failure New York Hear Association Class III IV , know active ( acute chronic ) uncontrolled severe infection , liver disease cirrhosis , decompensated liver disease , chronic hepatitis , know severely impaired lung function ( spirometry DLCO 50 % less normal O2 saturation 88 % less rest room air ) , active , bleed diathesis , chronic treatment corticosteroid , immunosuppressive agent , topical inhale corticosteroid allow , know history HIV seropositivity , patient receive live attenuate vaccine within 1 week start Everolimus . Patient would avoid close contact others receive live attenuate vaccine study , patient history primary malignancy , exception monmelanoma skin cancer , carcinoma situ cervix , uterus , breast patient disease free &gt; / 3 year , patient history non compliance medical regimen consider potentially unreliable able complete entire study , patient currently part participate clinical investigation investigational drug within 1 month prior dose , pregnant nursing ( lactate ) woman , woman childbearing potential ( WOCBP ) , define woman physiologically capable become pregnant , unless use highly effective method contraception dose study treatment . highly effective contraception method , male patient whose sexual partner ( ) WOCBP willing use adequate contraception , study 8 week end treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>Neurofibroma</keyword>
	<keyword>NF-1</keyword>
	<keyword>Everolimus</keyword>
	<keyword>mTOR inhibitor</keyword>
</DOC>